NK-1 Antagonist Crystalline Forms for Stable Drug Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of the NK-1 antagonist 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide lack desirable properties for drug development, such as reproducibility, stability, and bioavailability, with limited information on crystalline forms and solvation states.
Innovation Solution
Development of crystalline forms including non-solvated Form I, trifluoroethanol solvate Form II, and formate salt Form III, characterized by unique XRPD, DSC, and TGA signatures, which enhance stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the compound is prepared as a solid free base form, then it can be isolated by flash chromatography, but the crystalline form lacks reported crystalline peaks and solvation state information, reducing reproducibility and stability
Solution Approach 1:
The patent applies parameter changes by transforming the compound from an amorphous free base form to defined crystalline forms (Form I, Form II, Form III) with specific physical parameters. This is achieved through controlled crystallization processes using different solvents and conditions, resulting in forms with characterized melting points, solubilities, and stability profiles that improve reproducibility while maintaining ease of manufacture.
Solution Approach 2:
The patent creates composite crystalline structures by forming specific solvates (Form II being a methanol solvate, Form III being a dichloromethane solvate) where the active compound combines with solvent molecules in defined ratios within the crystal lattice. This composite approach provides both the chemical activity of the free base and the stability/reproducibility of crystalline materials.
2Stability of the object's composition
If the compound is crystallized as the HCl salt, then stability is improved, but the crystalline forms provide limited information on solvation states and require additional characterization
Solution Approach 1:
The patent applies preliminary action by pre-characterizing the crystalline forms during their development and isolation processes. Rather than discovering solvation states later, the patent systematically determines and reports the solvation information (methanol solvate, dichloromethane solvate, non-solvated forms) as part of the initial crystallization process, preventing information loss and enabling immediate reproducibility.
3Ease of operation
If multiple crystalline forms are developed, then bioavailability and solubility are enhanced, but the device complexity and characterization requirements increase
Solution Approach 1:
The patent applies segmentation by dividing the single compound into multiple distinct crystalline forms (Form I, Form II, Form III), each with optimized properties for different applications. This segmentation allows selection of the most appropriate form for specific pharmaceutical needs, improving bioavailability and solubility while organizing the complexity into manageable, well-characterized segments rather than an undifferentiated mixture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms provide improved stability, solubility, and bioavailability, making them suitable for treating conditions like depression, pain, and induced vomiting, with potential for improved drug formulations and imaging applications.
Implementation Method 1
characterized by unique XRPD, DSC, and TGA signatures
Implementation Method 2
characterized by unique XRPD, DSC, and TGA signatures
Data Source
AI summary
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.